NIH and NSF are often criticized for slow decisions, but a major reason for that is: experimental science is difficult and slow. Software people find this hard to comprehend, e.g. why would it take 10 years to find a new treatment? That's because you find an affected family (if it's hereditary), find appropriate controls, map the mutation, make a mouse model, use the mouse model to screen for pharmacological agents, and return to humans for testing them.
Microryza needs a vetting mechanism, at the very minimum, perhaps a dedicated science advisory board. Otherwise it runs a high risk of becoming a platform for snake oil salespeople.
aha!... now we are getting somewhere.